Role of Inhaled Corticosteroids in the Management of Serological Allergic Bronchopulmonary Aspergillosis (ABPA)

医学 过敏性支气管肺曲菌病 布地奈德 哮喘 奥马佐单抗 血清学 内科学 胸片 福莫特罗 免疫球蛋白E 不利影响 儿科 免疫学 抗体
作者
Ritesh Agarwal,Ajmal Khan,Ashutosh N. Aggarwal,Biman Saikia,Dheeraj Gupta,Arunaloke Chakrabarti
出处
期刊:Internal Medicine [Japanese Society of Internal Medicine]
卷期号:50 (8): 855-860 被引量:57
标识
DOI:10.2169/internalmedicine.50.4665
摘要

The treatment of choice for allergic bronchopulmonary aspergillosis (ABPA) is oral corticosteroids (OCS). However, they are associated with numerous adverse effects. Inhaled corticosteroids (ICS) are associated with fewer side-effects; however, their role in the management of ABPA remains controversial. In this retrospective study, we evaluate the role of high doses of ICS in serological ABPA (ABPA-S).Patients with ABPA-S were treated with a combination of formoterol/budesonide (24-1600 micrograms per day), and followed up with history, physical examination, chest radiograph and total IgE levels at 6, 12, 18 and 24 weeks. Asthma control was evaluated using the Global Initiative for Asthma (GINA) criteria. OCS were initiated if the IgE levels continued to rise after six months of therapy with ICS.There were 8 men and 13 women with a mean (SD) age of 39.3 (12.9) years. There was subjective improvement in all patients treated with ICS but none had complete control of asthma. After six months of therapy with ICS, the median IgE levels increased by 99.3%. After the initiation of OCS, there was complete resolution of asthma symptoms in 19 patients, and IgE levels fell by a median of 52.6% at six weeks. The median duration of follow-up was 15 months after OCS therapy. Eighteen patients achieved complete remission and three patients had a relapse in the first three months after stopping OCS. One patient required long-term OCS and was classified as glucocorticoid-dependent ABPA.High doses of ICS alone have no role in the management of ABPA-S and should not be used as first-line therapy. In patients receiving OCS or alternate therapy, ICS can be used as an add-on therapy for the control of symptoms of asthma.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
klb13应助它山凡溪寺采纳,获得10
1秒前
李爱国应助戒骄戒躁采纳,获得10
1秒前
2秒前
3秒前
4秒前
凯凯宝完成签到,获得积分10
4秒前
4秒前
5秒前
阿琦发布了新的文献求助10
5秒前
踏实的盼秋完成签到,获得积分10
6秒前
7秒前
凯凯宝发布了新的文献求助10
8秒前
酷波er应助武雨寒采纳,获得10
8秒前
11秒前
Lilyzi应助makenemore采纳,获得10
12秒前
enterdawn应助标致冰海采纳,获得10
13秒前
玉米完成签到 ,获得积分10
14秒前
英俊的铭应助开放的映波采纳,获得10
14秒前
意明发布了新的文献求助10
15秒前
16秒前
开心榴莲大王完成签到 ,获得积分10
16秒前
17秒前
好的完成签到,获得积分10
18秒前
18秒前
可爱的函函应助嘻嘻印采纳,获得10
19秒前
aaaxia完成签到,获得积分10
19秒前
ZHOUZHEN完成签到,获得积分10
20秒前
Arisqotle发布了新的文献求助10
21秒前
武雨寒发布了新的文献求助10
23秒前
24秒前
顺心曼雁完成签到 ,获得积分10
26秒前
pufanlg完成签到,获得积分10
26秒前
26秒前
孤独的立轩完成签到,获得积分10
27秒前
打打应助冬灵采纳,获得10
27秒前
29秒前
30秒前
开放的映波完成签到,获得积分20
30秒前
希望天下0贩的0应助意明采纳,获得10
30秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 870
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Fundamentals of Dispersed Multiphase Flows 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3254158
求助须知:如何正确求助?哪些是违规求助? 2896509
关于积分的说明 8292828
捐赠科研通 2565380
什么是DOI,文献DOI怎么找? 1392986
科研通“疑难数据库(出版商)”最低求助积分说明 652418
邀请新用户注册赠送积分活动 629856